Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

NCT01735071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Epithelial Cancer Recurrent

Interventions

DRUG: bevacizumab and trabectedin
DRUG: bevacizumab, trabectedin and carboplatin

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]
[object Object]